A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
NCT02334436
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
324
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL:
Botulinum toxin, Type A
OTHER:
0.9% sterile, unpreserved saline
Sponsor
Evolus, Inc.
Collaborators
[object Object]